COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Journal article

The global response to Coronavirus Disease 2019 (COVID-19) is now facing new challenges such as vaccine inequity and the emergence of SARS-CoV-2 variants of concern (VOCs). Preclinical models of disease, in particular animal models, are essential to investigate VOC pathogenesis, vaccine correlates of protection and postexposure therapies. Here, we provide an update from the World Health Organization (WHO) COVID-19 modeling expert group (WHO-COM) assembled by WHO, regarding advances in preclinical models. In particular, we discuss how animal model research is playing a key role to evaluate VOC virulence, transmission and immune escape, and how animal models are being refined to recapitulate COVID-19 demographic variables such as comorbidities and age

Authors: Maisonnasse, P; Aldon, Y; Marc, A; Marlin, R; Dereuddre-Bosquet, N

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Nature Research
• Journal: Nature Communications
• Volume: 12
• Issue: 1
• Pages: 6097-6097
• Article number: 6097
• Publication date: 2021-10-20
• DOI: 10.1038/s41467-021-26354-0
• EISSN: 2041-1723
• ISSN: 2041-1723
• Language: English
• Keywords: Antibody; Coronavirus disease 2019 (COVID-19); Pathology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Lung; Respiratory system; Neutralizing antibody; Internal medicine; Monoclonal antibody; Biology; Virology; Medicine; Pharmacology; Immunology; In vivo